Search

for
Search:

GlossarySonidegib (LDE225)

inhibits Hedgehog pathway to treat advanced basal cell carcinoma

Sonidegib, also known as Odomzo, is a medication used to treat advanced basal cell carcinoma, a type of skin cancer. It works by inhibiting the Hedgehog signaling pathway, which is crucial for the growth and survival of cancer cells.

Related Terms

Learn

0 / 0 results

— no results

Research

5 / 13 results

research P62 Pre-Clinical Pharmacological and Skin Penetration Profile of LDE255, a Novel and Specific Smoothened Antagonist

June 2010 in “Melanoma research”

LDE225 is a promising skin-applied treatment for basal cell carcinoma with good skin penetration and effectiveness.

research Management of Cutaneous and Extracutaneous Side Effects of Smoothened Inhibitor Therapy for Advanced Basal Cell Carcinoma

16 citations , March 2015 in “Clinical Cancer Research”

The document concludes that side effects from Smoothened inhibitor drugs for skin cancer are reversible and can be managed with a team approach to maintain quality of life.

research Adverse Hair Reactions to New Targeted Therapies for Cancer

1 citations , March 2019 in “Actas Dermo-Sifiliográficas”

New cancer treatments are less harmful to hair but can still cause hair loss, color, shape, and growth changes.

research Roles of the Hedgehog Signaling Pathway in Cutaneous Physiology and Oncology

June 2019 in “International journal of dermatology and venereology”

The Hedgehog Signaling Pathway is important for skin and hair development and skin cancer treatment, but more research is needed to understand it fully.

research Characterization and Management of Hedgehog Pathway Inhibitor-Related Adverse Events in Patients With Advanced Basal Cell Carcinoma

127 citations , August 2016 in “The oncologist”

Understanding and managing side effects of hedgehog pathway inhibitors can improve treatment for advanced basal cell carcinoma.

View more "lde225" in research →

Community Join

0 / 0 results

— no results